GU Cancers 2025 | RAD-IO: assessing the feasibility of durvalumab with CRT in bladder cancer
Nicholas James, MBBS, PhD, FRCP, FRCR, Institute of Cancer Research, London, UK, discusses the RAD-IO trial (ISRCTN: 43698103), which investigates the addition of durvalumab to standard chemoradiotherapy (CRT) for bladder cancer. Findings suggest that the treatment schedule, including neo-adjuvant, synchronous, and adjuvant durvalumab, was deliverable with full-dose CRT. Most participants completed treatment as planned, with minimal toxicity-related interruptions. Recruitment continues in the single-arm efficacy phase, with further results anticipated. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
